SERES THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9199 USD | -0.49% |
|
-9.81% | -34.29% |
| May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
| May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 241.5 | 2,236 | 765.1 | 697.7 | 181 | 139.3 | - | - |
| Enterprise Value (EV) 1 | 171.4 | 2,145 | 634.3 | 697.3 | 266.9 | 265.4 | 332.8 | 247.6 |
| P/E ratio | -2.78 x | -21.9 x | -11.6 x | -2.42 x | -1.57 x | -0.89 x | -1.29 x | 18.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7 x | 67.3 x | 5.28 x | 97.9 x | 1.43 x | 1,908 x | 30.9 x | 1.44 x |
| EV / Revenue | 4.97 x | 64.6 x | 4.38 x | 97.8 x | 2.11 x | 3,636 x | 73.9 x | 2.55 x |
| EV / EBITDA | -2.67 x | -26.3 x | -10.8 x | -2.91 x | -2.78 x | -1.93 x | -2.79 x | -21.8 x |
| EV / FCF | -2.21 x | -22.8 x | -9.58 x | -2.92 x | -2.13 x | -2.71 x | -18 x | 2.97 x |
| FCF Yield | -45.2% | -4.39% | -10.4% | -34.2% | -47% | -36.9% | -5.56% | 33.7% |
| Price to Book | - | - | - | - | -4.21 x | -28.2 x | 5.8 x | 3.43 x |
| Nbr of stocks (in thousands) | 70,011 | 91,248 | 91,847 | 124,592 | 129,257 | 151,448 | - | - |
| Reference price 2 | 3.450 | 24.50 | 8.330 | 5.600 | 1.400 | 0.9199 | 0.9199 | 0.9199 |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 34.5 | 33.22 | 144.9 | 7.128 | 126.3 | 0.073 | 4.502 | 97 |
| EBITDA 1 | -64.27 | -81.55 | -58.55 | -239.9 | -96.14 | -137.6 | -119.5 | -11.37 |
| EBIT 1 | -71.88 | -88.13 | -64.49 | -246.5 | -102.4 | -151.5 | -137.8 | -3.422 |
| Operating Margin | -208.31% | -265.33% | -44.5% | -3,458.05% | -81.05% | -207,472.33% | -3,059.63% | -3.53% |
| Earnings before Tax (EBT) 1 | -70.28 | -89.13 | -65.58 | -250.2 | -113.7 | -166 | -162 | 14.28 |
| Net income 1 | -70.28 | -89.13 | -65.58 | -250.2 | -113.7 | -163.6 | -153.4 | -13.41 |
| Net margin | -203.68% | -268.33% | -45.25% | -3,509.5% | -90.02% | -224,055.82% | -3,406.6% | -13.83% |
| EPS 2 | -1.240 | -1.120 | -0.7200 | -2.310 | -0.8900 | -1.032 | -0.7129 | 0.0504 |
| Free Cash Flow 1 | -77.52 | -94.2 | -66.22 | -238.6 | -125.3 | -98 | -18.5 | 83.5 |
| FCF margin | -224.67% | -283.61% | -45.7% | -3,347.88% | -99.21% | -134,246.58% | -410.9% | 86.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.221 | 1.493 | 1.216 | 3.444 | 0.975 | - | 126.5 | 0.31 | 0.064 | - | -0.2261 | 0.0689 | 0.2303 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -49.43 | -55.75 | -63.32 | -59.11 | -68.31 | -70.57 | 49.52 | -47.41 | -33.93 | -39.59 | -38.83 | -36.93 | -35.91 | -41.98 | -43.13 |
| Operating Margin | -684.56% | -3,734.16% | -5,207.65% | -1,716.23% | -7,005.85% | - | 39.16% | -15,294.52% | -53,009.38% | - | 17,169.1% | -53,630.85% | -15,592.51% | - | - |
| Earnings before Tax (EBT) 1 | -50 | -56.62 | -64.74 | -60 | -68.8 | -71.17 | 46.55 | -47.85 | -41.25 | -40.13 | -42.05 | -41.49 | -41.1 | -46.08 | -48.08 |
| Net income 1 | -50 | -56.62 | -64.74 | -60 | -68.8 | -71.17 | 46.55 | -47.85 | -41.25 | -40.13 | -41.96 | -40.72 | -39.87 | -46.08 | -48.08 |
| Net margin | -692.44% | -3,792.63% | -5,323.6% | -1,742.22% | -7,056% | - | 36.81% | -15,436.77% | -64,450% | - | 18,553.88% | -59,133.02% | -17,310.89% | - | - |
| EPS 2 | -0.5500 | -0.6100 | -0.7000 | -0.4900 | -0.5400 | -0.5700 | 0.3600 | -0.3700 | -0.3200 | -0.2700 | -0.2750 | -0.2433 | -0.2350 | -0.2467 | -0.2300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/4/22 | 8/3/22 | 11/2/22 | 3/7/23 | 5/9/23 | 8/8/23 | 11/2/23 | 3/5/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 86 | 126 | 193 | 108 |
| Net Cash position 1 | 70.2 | 91 | 131 | 0.44 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.8942 x | -0.9164 x | -1.62 x | -9.52 x |
| Free Cash Flow 1 | -77.5 | -94.2 | -66.2 | -239 | -125 | -98 | -18.5 | 83.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | -521% | -101% |
| ROA (Net income/ Total Assets) | - | - | - | - | -32.2% | -58.2% | -45.4% | -28.9% |
| Assets 1 | - | - | - | - | 353.7 | 281.2 | 338.1 | 46.37 |
| Book Value Per Share 2 | - | - | - | - | -0.3300 | -0.0300 | 0.1600 | 0.2700 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1 | 0.59 | 9.57 | 9.82 | 7.98 | 7.61 | 4.03 | 3.77 |
| Capex / Sales | 2.9% | 1.78% | 6.6% | 137.78% | 6.31% | 10,420.55% | 89.53% | 3.89% |
| Announcement Date | 3/2/20 | 3/2/21 | 3/1/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.9199
USD
Average target price
6.2
USD
Spread / Average Target
+573.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.29% | 139M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.56% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- MCRB Stock
- Financials Seres Therapeutics, Inc.
